Telo Genomics Corp. develops diagnostic and prognostic tests for human disease using 3D analysis of chromosomal telomeres. News about TDSGF centers on the company’s telomere analytics platform, including TeloView® and blood-based minimal residual disease testing for multiple myeloma.
Recurring updates include retrospective clinical studies and academic collaborations, presentations at hematology and myeloma meetings, laboratory-capacity developments, and corporate governance changes. Company announcements also describe work with circulating tumor cells, individual-cell risk profiling, and the use of liquid-biopsy workflows to assess relapse risk in oncology.
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
-
News
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
FAQ
What is the current stock price of TELO GENOMICS (TDSGF)?
TELO GENOMICS (TDSGF) last closed at $0.0360.
What is the market cap of TELO GENOMICS (TDSGF)?
The market cap of TELO GENOMICS (TDSGF) is approximately $3.6M.